IMR Press / FBS / Volume 15 / Issue 2 / DOI: 10.31083/j.fbs1502007
Open Access Original Research
The Impact of Heparin Therapy in Deceased Donors on Early Graft Survival for Kidney and Liver Recipients: A Clinical Trial Study
Show Less
1 Medical Ethics and Law Research Center, Shaheed Beheshti University of Medical Sciences, 1985717443 Tehran, Iran
2 Organ Procurement Unit, Sina Hospital, Tehran University of Medical Sciences, 46911 Tehran, Iran
3 Cardiovascular Research Foundation of Southern California, Beverly Hills, CA 90210, USA
4 Southern California Medical Education Consortium, Temecula Valley Hospital, Universal Health System, Temecula, CA 92592, USA
5 Anesthesia, Critical Care and Pain Management Research Center, Tehran University of Medical Sciences, 1136746911 Tehran, Iran
6 Iranian Tissue Bank & Research Center, Tehran University of Medical Sciences, 1419733141 Tehran, Iran
*Correspondence: sanaz_dehghani2002@yahoo.com (Sanaz Dehghani)
Front. Biosci. (Schol Ed) 2023, 15(2), 7; https://doi.org/10.31083/j.fbs1502007
Submitted: 12 February 2023 | Revised: 19 April 2023 | Accepted: 8 June 2023 | Published: 25 June 2023
Copyright: © 2023 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license.
Abstract

Background: Significant hemodynamic, hormonal, and metabolic impairment of a brain-dead organ donor is often associated with the deterioration of graft viability. This study aimed to compare the effect of heparin therapy as a therapeutic dose after brain death confirmation on early graft survival in kidney and liver recipients. Method and Materials: The deceased donors were sorted into two groups based on their D-dimer level. After confirming brain death, one group was given a heparin injection (case group), while the other group did not receive any heparin (control group). A total of 71 brain death donors and matched kidney and liver transplants were included in the case group. A total of 43 brain death donors and matched kidney and liver transplants were included in the control group. A total of 5000 units of heparin were administered every 6 hours to the deceased donor case group. Results: The mean age of the case and control groups were 36.27 ± 16.13 and 36.15 ± 18.45, respectively. An independent t test showed that there were no differences between the number of procured organs in both groups (p = 0.29). There was no significant difference between the graft survival rate and the doses of heparin injection to the liver recipients (p = 0.06). However, a significant difference was revealed between the graft survival rate and the dose of heparin injection (p = 0.004) in kidney recipients. Conclusions: The data suggest that administering low therapeutic doses of heparin to donors before organ donation may potentially prevent thrombosis and provide a protective benefit. We showed that heparin therapy had no significant effect on the number of donated organs and graft survival.

Keywords
brain death
heparin
transplantation
kidney
liver
Share
Back to top